Physician profile
Scott A Ghere
NPI 1124286919
$27,099.70
in general payments reported to CMS, 2019-2025
53 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,783 · 2020: $3,941 · 2021: $6,420 · 2022: $4,713 · 2023: $4,259 · 2024: $2,236 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,166 · Education: $76.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,165.93 |
| Education | $76.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,418.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,167.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,071.21 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceuticals, INC. | $1,934.93 | 2020-2021 | |
| Abbvie INC. | $1,857.45 | 2019-2025 | |
| Pfizer INC. | $1,582.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,575.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,493.90 | 2019-2024 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $1,161.94 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $850.35 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $759.78 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Sanofi-Aventis U.S. LLC | $633.75 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $615.98 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $597.57 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $567.77 | 2022-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ghere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.